The President’s actions (or distractions) may be detrimental to Western medical device companies.
With the increase of diabetes prevalence in Asia and the rise of Asia’s middle classes, the demand for newer and better treatments will provide opportunities for Western medtech companies.
As standalone software becomes increasingly sophisticated, a number of regulatory bodies have begun to draft separate guidelines to ensure quality control, expedite product approval, and improve patient access to new technologies.
Global sports medicine is predicted to grow to around $35 billion by 2022, with the Asian market growing at a compound annual growth rate of nearly 7 percent.
As Asians get wealthier and more concerned about how they look, opportunities in Asia’s aesthetic market will skyrocket.
Growth of the Asian cloud computing market is expected to accelerate as healthcare providers streamline their operations in today’s paperless world.
Tips to navigate what can be a grueling undertaking.
Earlier this year, the CFDA introduced significant changes to the drug and device approval process.
China’s medtech influence is beginning to threaten the West’s dominance.
As the continent becomes a bigger player, western companies should explore the potential prospects.